{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:45:57Z","timestamp":1794955557088,"version":"4.9.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common treatment for patients suffering from different hematological disorders. Allo-HCT in combination with hematopoietic stem cell (HSC) gene therapy is considered a promising treatment option for millions of patients with HIV+ and acute myeloid leukemia. Most currently available HSC gene therapy approaches target CD34-enriched cell fractions, a heterogeneous mix of mostly progenitor cells and only very few HSCs with long-term multilineage engraftment potential. As a consequence, gene therapy approaches are currently limited in their HSC targeting efficiency, very expensive consuming huge quantities of modifying reagents, and can lead to unwanted side effects in nontarget cells. We have previously shown that purified CD34<jats:sup>+<\/jats:sup>CD90<jats:sup>+<\/jats:sup>CD45RA<jats:sup>\u2212<\/jats:sup> cells are enriched for multipotent HSCs with long-term multilineage engraftment potential, which can reconstitute the entire hematopoietic system in an autologous nonhuman primate transplant model. Here, we tested the feasibility of transplantation with purified CD34<jats:sup>+<\/jats:sup>CD90<jats:sup>+<\/jats:sup>CD45RA<jats:sup>\u2212<\/jats:sup> cells in the allogeneic setting in a nonhuman primate model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>To evaluate the feasibility of this approach, CD34<jats:sup>+<\/jats:sup>CD90<jats:sup>+<\/jats:sup>CD45RA<jats:sup>\u2212<\/jats:sup> cells from 2 fully major histocompatibility complex-matched, full sibling rhesus macaques were sort-purified, quality controlled, and transplanted. Engraftment and donor chimerism were evaluated in the peripheral blood and bone marrow of both animals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Despite limited survival due to infectious complications, we show that the large-scale sort-purification and transplantation of CD34<jats:sup>+<\/jats:sup>CD90<jats:sup>+<\/jats:sup>CD45RA<jats:sup>\u2212<\/jats:sup> cells is technically feasible and leads to rapid engraftment of cells in bone marrow in the allogeneic setting and absence of cotransferred T cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>We show that purification of an HSC-enriched CD34<jats:sup>+<\/jats:sup> subset can serve as a potential stem cell source for allo-HCTs. Most importantly, the combination of allo-HCT and HSC gene therapy has the potential to treat a wide array of hematologic and nonhematologic disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001029","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T15:38:27Z","timestamp":1608737907000},"page":"e579","source":"Crossref","is-referenced-by-count":11,"title":["Isolation of a Highly Purified HSC-enriched CD34+CD90+CD45RA\u2212 Cell Subset for Allogeneic Transplantation in the Nonhuman Primate Large-animal Model"],"prefix":"10.1097","volume":"6","author":[{"given":"Stefan","family":"Radtke","sequence":"first","affiliation":[{"name":"Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Colonna","sequence":"additional","affiliation":[{"name":"Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA."},{"name":"Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Research Institute, Seattle, WA."},{"name":"Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anai M.","family":"Perez","sequence":"additional","affiliation":[{"name":"Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA."},{"name":"Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Research Institute, Seattle, WA."},{"name":"Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie S.","family":"Kean","sequence":"additional","affiliation":[{"name":"Ben Towne Center for Childhood Cancer Research, Seattle Children\u2019s Research Institute, Seattle, WA."},{"name":"Department of Pediatrics, University of Washington, Seattle, WA."},{"name":"Department of Medicine, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Kiem","sequence":"additional","affiliation":[{"name":"Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA."},{"name":"Department of Medicine, University of Washington, Seattle, WA."},{"name":"Department of Pathology, University of Washington School of Medicine, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8]]},"reference":[{"key":"R1-20231127","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients.","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20231127","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art.","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"R3-20231127","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-111-12-973","article-title":"Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma.","volume":"111","author":"Holland","year":"1989","journal-title":"Ann Intern Med"},{"key":"R4-20231127","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation.","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20231127","first-page":"669","article-title":"Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS.","volume":"12","author":"Contu","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"R6-20231127","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcyt.2017.05.013","article-title":"CCR5-edited gene therapies for HIV cure: closing the door to viral entry.","volume":"19","author":"Haworth","year":"2017","journal-title":"Cytotherapy"},{"key":"R7-20231127","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2015-09-672337","article-title":"Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.","volume":"127","author":"Peterson","year":"2016","journal-title":"Blood"},{"key":"R8-20231127","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2019.04.010","article-title":"Lessons from London and Berlin: designing a scalable gene therapy approach for HIV cure.","volume":"24","author":"Peterson","year":"2019","journal-title":"Cell Stem Cell"},{"key":"R9-20231127","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia.","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"R10-20231127","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","article-title":"Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2.","volume":"33","author":"Humbert","year":"2019","journal-title":"Leukemia"},{"key":"R11-20231127","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies.","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-20231127","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/stem.1661","article-title":"Concise review: evidence for CD34 as a common marker for diverse progenitors.","volume":"32","author":"Sidney","year":"2014","journal-title":"Stem Cells"},{"key":"R13-20231127","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1038\/mtm.2016.7","article-title":"Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS.","volume":"3","author":"Peterson","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R14-20231127","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt.3408","article-title":"Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.","volume":"33","author":"Wang","year":"2015","journal-title":"Nat Biotechnol"},{"key":"R15-20231127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells.","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"R16-20231127","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage.","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"R17-20231127","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nbt0315-217","article-title":"$1-million price tag set for Glybera gene therapy.","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"key":"R18-20231127","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrd3835-c1","article-title":"Regulatory evaluation of Glybera in Europe - two committees, one mission.","volume":"12","author":"Melchiorri","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"R19-20231127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/15665232113136660005","article-title":"General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.","volume":"13","author":"Baldo","year":"2013","journal-title":"Curr Gene Ther"},{"key":"R20-20231127","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions.","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol"},{"key":"R21-20231127","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"R22-20231127","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"R23-20231127","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"R24-20231127","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity.","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"R25-20231127","doi-asserted-by":"crossref","first-page":"e947749","DOI":"10.4161\/21675511.2014.947749","article-title":"Gene therapy for Wiskott-Aldrich Syndrome-long-term reconstitution and clinical benefits, but increased risk for leukemogenesis.","volume":"2","author":"Braun","year":"2014","journal-title":"Rare Dis"},{"key":"R26-20231127","doi-asserted-by":"crossref","first-page":"eaan1145","DOI":"10.1126\/scitranslmed.aan1145","article-title":"A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates.","volume":"9","author":"Radtke","year":"2017","journal-title":"Sci Transl Med"},{"key":"R27-20231127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2018.12.003","article-title":"MISTRG mice support engraftment and assessment of nonhuman primate hematopoietic stem and progenitor cells.","volume":"70","author":"Radtke","year":"2019","journal-title":"Exp Hematol"},{"key":"R28-20231127","doi-asserted-by":"crossref","first-page":"eaaw3768","DOI":"10.1126\/scitranslmed.aaw3768","article-title":"Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.","volume":"11","author":"Humbert","year":"2019","journal-title":"Sci Transl Med"},{"key":"R29-20231127","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1182\/blood-2007-09-115022","article-title":"Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors.","volume":"111","author":"Trobridge","year":"2008","journal-title":"Blood"},{"key":"R30-20231127","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/j.1600-6143.2010.03272.x","article-title":"An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching.","volume":"10","author":"Larsen","year":"2010","journal-title":"Am J Transplant"},{"key":"R31-20231127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2184.2010.00726.x","article-title":"Pulse exposure of haematopoietic grafts to prostaglandin E2 in vitro facilitates engraftment and recovery.","volume":"44 Suppl 1","author":"Pelus","year":"2011","journal-title":"Cell Prolif"},{"key":"R32-20231127","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2013-07-515288","article-title":"Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness.","volume":"122","author":"Hoggatt","year":"2013","journal-title":"Blood"},{"key":"R33-20231127","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1038\/s41467-018-06736-7","article-title":"Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.","volume":"9","author":"Colonna","year":"2018","journal-title":"Nat Commun"},{"key":"R34-20231127","doi-asserted-by":"crossref","first-page":"eaan3085","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.","volume":"9","author":"Tkachev","year":"2017","journal-title":"Sci Transl Med"},{"key":"R35-20231127","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00251-005-0787-1","article-title":"Microsatellite typing of the rhesus macaque MHC region.","volume":"57","author":"Penedo","year":"2005","journal-title":"Immunogenetics"},{"key":"R36-20231127","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1600-6143.2011.03873.x","article-title":"Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old.","volume":"12","author":"Kean","year":"2012","journal-title":"Am J Transplant"},{"key":"R37-20231127","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nature13824","article-title":"Clonal dynamics of native haematopoiesis.","volume":"514","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"R38-20231127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.stem.2016.04.016","article-title":"In vivo tracking of human hematopoiesis reveals patterns of clonal dynamics during early and steady-state reconstitution phases.","volume":"19","author":"Biasco","year":"2016","journal-title":"Cell Stem Cell"},{"key":"R39-20231127","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41591-018-0195-3","article-title":"Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans.","volume":"24","author":"Scala","year":"2018","journal-title":"Nat Med"},{"key":"R40-20231127","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model.","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"R41-20231127","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0301-472X(00)00169-7","article-title":"Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.","volume":"28","author":"Michallet","year":"2000","journal-title":"Exp Hematol"},{"key":"R42-20231127","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1083-8791(00)70008-5","article-title":"Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.","volume":"6","author":"Negrin","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"R43-20231127","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/bbmt.2001.v7.pm11787531","article-title":"Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin\u2019s lymphoma.","volume":"7","author":"Vose","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R44-20231127","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2016-09-743112","article-title":"Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.","volume":"129","author":"Mehta","year":"2017","journal-title":"Blood"},{"key":"R45-20231127","article-title":"Sort-purification of human CD34+CD90+ cells reduces target cell population and improves lentiviral transduction.","author":"Radtke","year":"2019","journal-title":"bioRxiv"},{"key":"R46-20231127","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.ymthe.2018.08.025","article-title":"Sorting out the best: enriching hematopoietic stem cells for gene therapy and editing.","volume":"26","author":"Radtke","year":"2018","journal-title":"Mol Ther"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:06:02Z","timestamp":1701122762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001029","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}